1431542-27-6

Basic information

• Product Name: 1-{4-[3-(6-bromo-quinazolin-4-yl)-benzoyl]-piperazine-1-yl}-ethanone
• Synonyms: 1-{4-[3-(6-bromo-quinazolin-4-yl)-benzoyl]-piperazine-1-yl}-ethanone
• CAS NO: 1431542-27-6
• Molecular Weight: 439.311
• Mol File: 1431542-27-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1-{4-[3-(6-bromo-quinazolin-4-yl)-benzoyl]-piperazine-1-yl}-ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-{4-[3-(6-bromo-quinazolin-4-yl)-benzoyl]-piperazine-1-yl}-ethanone(1431542-27-6)
• EPA Substance Registry System: 1-{4-[3-(6-bromo-quinazolin-4-yl)-benzoyl]-piperazine-1-yl}-ethanone(1431542-27-6)

Safety Data

• Hazardous Substances Data: 1431542-27-6(Hazardous Substances Data)

Upstream product

• 39263-32-6 2-amino-5-bromobenzonitrile 
• 32084-59-6 6-bromoquinazolin-4(3H)-one 
• 38267-96-8 6-bromo-4-chloroquinozoline 
• 4334-87-6 [3-(ethoxycarbonyl)phenyl]boronic acid 
• 1431542-29-8 3-(6-bromo-quinazolin-4-yl)-benzoic acid ethyl ester 
• 13889-98-0 N-acetylpiperidine 
• 1431542-28-7 3-(6-bromo-quinazolin-4-yl)-benzoic acid 

Downstream Products

• 1431540-99-6 5-{4-[3-(4-acetyl-piperazine-1-carbonyl)-phenyl]-quinazolin-6-yl}-2-methoxy-nicotinonitrile 

Relevant articles and documents

“On-Water” Palladium-Catalyzed Tandem Cyclization Reaction for the Synthesis of Biologically Relevant 4-Arylquinazolines

The quinazoline scaffold is prevalent in pharmaceutically relevant molecules that show diverse biological activities. Herein, we report an efficient “on-water” palladium-catalyzed tandem cyclization reaction from commercially available arylboronic acids and benzonitriles that enable the rapid access to 4-arylquinazoline scaffolds in good to excellent yields (45 examples, up to 98 % yield). This protocol has shown good functional group tolerance and broad substrate scope. The reaction was also performed on a gram scale and successfully applied to the synthesis of the highly potent and selective PI3Kδ inhibitor N11, showing the practicability and synthetic utility of the protocol. In this reaction, the quinazoline scaffold is efficiently constructed with the simultaneous formation of one C?C bond and one C?N bond. Collectively, the protocol could serve as an alternative strategy to synthesize biologically important quinazoline scaffolds.

Use of Inhibitors of the Activity or Function of PI3K

The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.

Use of inhibitors of the activity or function of PI3K

The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.